Exhibit 10.2


 





 


AMENDMENT TO EMPLOYMENT AGREEMENT


 


THIS
AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made on this 27th day of November, 2018
(the “Effective Date”), by and between Marker Therapeutics, Inc., a Delaware corporation (the “Company”),
and Michael J. Loiacono, an individual (the “Executive”), and amends that certain Employment Agreement between
the Company and the Executive, dated August 25, 2016 (the
 “Employment Agreement”).


 


RECITALS:


 


WHEREAS, the
Company and the Executive entered into the Employment Agreement on August 25, 2016; and


 


WHEREAS, the
Company desires to appoint a new Chief Financial Officer, however, the Company desires to retain Executive to continue to serve
as the Company’s Chief Accounting Officer; and


 


WHEREAS, the
Company and the Executive wish to amend the Executive’s Employment Agreement, to provide for Executive’s services as
Chief Accounting Officer and thereby the relinquishment of the office of Chief Financial Officer as provided herein.


 


NOW THEREFORE,
the Executive and the Company for themselves, their heirs, successors and assigns, in consideration of their mutual promises contained
herein, intending to be legally bound, hereby agree that the Employment Agreement is hereby amended as follows:


 


1.       Section
1 and 2 of the Employment Agreement are hereby deleted and replaced in their entirety with the following:


 


2.       EMPLOYMENT. The
Company will employ the Executive as the Chief Accounting Officer of the Company, and the Executive agrees to serve in such capacities
and provide his services to the Company on the terms and conditions set forth in this Agreement.


 


3.       POSITION
AND DUTIES. On and after the date of this Agreement, the Executive will serve as the Chief Accounting Officer of the Company.
The Executive agrees that during the Term (as defined below) he shall dedicate his full business time, attention and energies to
performing his duties to the Company, as prescribed by the Chief Executive Office (the “CEO”) and Chief Financial
Officer (the “CFO”). The Executive will manage the accounting affairs of the Company and perform the duties
typically assigned to the Chief Accounting Officer of a similarly situated company in the Company’s industry. The Executive
shall also perform such other reasonable duties as may hereafter be assigned to him by the CEO or CFO, consistent with his abilities
and position as the Chief Accounting Officer and providing such further services to the Company as may reasonably be requested
of him. The Executive will report to the CEO of the Company, and carry out the financial decisions and otherwise abide by
and enforce the lawful rules and policies of the Company.


 






     


     


    




 


The Executive shall
devote his best business efforts to the business and affairs of the Company and, during the Term, shall observe at all times the
covenants regarding non-competition, and confidentiality provided in Sections 5, 6 and 7 below. The Company and Executive
acknowledge and agree that, during the Term, Executive shall be permitted to (i) serve on corporate, civic or charitable boards
or committees, and (ii) manage passive personal investments, so long as any such activities do not unduly interfere with the
performance of Executive’s responsibilities as an employee of the Company in accordance with this Agreement.


 


2.       Section
4(a)-(b) of the Employment Agreement are hereby deleted and replaced in their entirety with the following:


 


4. COMPENSATION AND BENEFITS.


 


(a) Base Salary. At
the Effective Date, the Executive’s annual base salary shall be two hundred seventy five thousand dollars ($275,000) per
year, which shall be paid bi-weekly by the Company to the Executive in accordance with the Company’s customary payroll practices,
subject to customary withholding as required by applicable law. This annual base salary shall be reviewed by the CEO periodically,
and the CEO may increase the Executive’s annual base salary from time to time as the CEO deems to be appropriate subject
to performance and market conditions. The Executive’s salary will not be reduced without Executive’s prior written
consent except that the Board may, in its sole discretion, reduce Executive’s base salary in connection with a salary reduction
applicable to all Company senior executive officers in substantially the same proportions.


 


(b) Annual Incentive
Compensation. During the Term, the Executive shall be eligible for an annual performance bonus of up to thirty-five percent
(35%) of the Executive’s annual base salary, based on goals and other conditions as the Board (or duly authorized committee
thereof), shall determine in its sole discretion on an annual basis (the “Annual Performance Bonus”). The Annual
Performance Bonus will be payable in the form of cash or fully-vested shares of the Company’s common stock, or a combination
thereof, at the Board’s (or duly authorized committee thereof), discretion, in any case to be paid or delivered as soon as
practicable after the end of the year in which it is earned and in any event not more than ninety (90) days after the end of such
year. Payment of the Annual Performance Bonus shall be expressly conditioned upon Executive’s employment with the Company
on the date that the Annual Performance Bonus is paid, except as provided in Section 9(b) and Section 10(a) below


 


Any such Annual Performance
Bonus, as well as any equity awards which are granted to the Executive or which become vested as a result of the satisfaction of
financial performance goals of the Company, shall be subject to the Company’s Policy on Recoupment of Executive Incentive
Compensation, and that the Executive shall be obligated to repay to the Company, any and all amounts received with respect to the
Annual Performance Bonus or performance-based equity awards, to the extent such a repayment is required by the terms of the Policy
on Recoupment of Executive Incentive Compensation, as such policy may be amended from time to time.


 






    2 


     


    

 


3.       Section
9 of the Employment Agreement is hereby amended to read as follows in its entirety:


 


9.       SEVERANCE
PAY.


 


(a)       In
the event the Executive’s employment with the Company is terminated by the Company during the Term for Cause (as defined
in Section 8(d) above), or by the Executive other than for Good Reason (as defined in Section 8(e) above), the compensation
and benefits the Executive shall be entitled to receive from the Company shall be limited to:


 


(i)       his
then-current annual base salary pursuant to Section 4 through the date of termination, payable in accordance with the Company’s
standard payroll practices;


 


(ii)       any
reimbursable expenses for which the Executive has not yet been reimbursed as of the date of termination; and


 


(iii)       any
other rights and vested benefits (if any) provided under employee benefit plans and programs of the Company, determined in accordance
with the applicable terms and provisions of such plans and programs.


 


Any annual performance
bonus under Section 4(b) earned for a prior year but not yet paid by the Company shall be forfeited if the Executive’s
employment with the Company is terminated by the Company for Cause or is terminated by the Executive for other than Good Reason.
If the Executive’s employment with the Company is terminated during the Term due to death or Disability, in addition to the
amounts in Subsection (a) of this Section 9, the Executive shall also be entitled to receive any annual performance
bonus that, as of the date of termination, has been earned by the Executive but has not yet been paid by the Company to the Executive
with such payments being made in the form determined by the Board as provided in Section 4(b).


 


(b)       If
the Executive’s employment with the Company is terminated during the Term, either by the Company without Cause or by the
Executive for Good Reason, in addition to the amounts in Subsection (a) of this Section 9, the Executive shall also
be entitled to receive severance pay equal to twelve (12) months of his annual base salary pursuant to Section 4, at the
rate in effect on the date of termination. This severance pay shall be paid to the Executive in cash in a single lump sum payment,
within sixty (60) days after the date of the termination of the Executive’s employment with the Company, but no earlier than
fifteen (15) days after the Executive’s execution and non-revocation of a general release of all claims against the Company,
its officers, directors, employees and affiliates, in form and substance satisfactory to the Company (the “Release”).
In addition, the Executive shall also receive upon termination any annual performance bonus that, as of the date of termination,
has been earned by the Executive but has not yet been paid by the Company to the Executive for the calendar year prior to the calendar
year in which termination occurs. For the calendar year in which termination occurs, Executive shall receive an Annual Performance
Bonus payable at the highest performance amount for the pro rata portion of the calendar year Executive served the Company, provided
that, the Executive has served a minimum of six months during the calendar year of any termination under this subsection. Any applicable
performance bonus is to be paid in such form as provided in Section 4(b). In addition, the Company shall pay the cost for
Executive to continue his health insurance benefits under COBRA for a period of twelve (12) months after termination of employment,
or the Company will fund an alternative health care insurance plan for the same dollar amount as would be payable under COBRA for
such period.


 






    3 


     


    

 


		(c)	If the Company exercises its right to provide Executive with a termination notice pursuant to Section
3, in addition to the amounts in Subsection (a) of this Section 9, at termination, Executive shall also be entitled to receive
severance pay equal to twelve months of his annual base salary at the rate in effect at termination payable in twelve equal monthly
payments.






 


(d)       Notwithstanding
anything in this Agreement to the contrary, it will be a condition to the Executive’s right to receive any severance benefits
under Subsections (b) and (c) of this Section 9 that he execute and deliver the Release to the Company upon his separation
from service, and that he does not revoke the Release during the fifteen (15) day period thereafter. Subject to Section 14
below, the severance payments under this Section 9 will be made no earlier than fifteen (15) days after the Executive has
executed, delivered and not revoked the Release as required under this Section 9.


 


4.       Except
as expressly amended by this Amendment, the Employment Agreement shall continue and remain in full force and effect.


 


 


 


[SIGNATURE PAGE TO FOLLOW]


 


 


 




    4 


     


    

 


IN WITNESS WHEREOF,
the Parties have executed this Agreement as of the date first written above, to be effective on the Effective Date, for the purposes
herein contained.


 










	COMPANY –Marker Therapeutics, Inc.	 	EXECUTIVE	 
	 	 	 	 	 
	 	 	 	 	 
	By:	/s/Peter L. Hoang	 	/s/Michael J. Loiacono	 
	Name: 	Peter L. Hoang	 	Name: Michael J. Loiacono	 
	Title: 	Chief Executive Officer	 	 	 




 


 


 


 


 


 


 


 





[Signature Page to Amendment to Employment
Agreement]